Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Novartis has agreed to a deal worth up to $7.8 billion to license a messenger RNA drug candidate from Abogen Biosciences, also securing options for future therapies. This move highlights a trend of major pharmaceutical companies seeking new drug candidates from Chinese biotechnology firms to bolster their pipelines.
Swiss drugmaker Novartis has struck a deal valued at up to $7.8 billion to license a drug candidate from China's Abogen Biosciences, including an upfront payment of $575 million and options over future therapies. This partnership represents the latest collaboration between a major Western pharmaceutical company and a C
Abogen has entered into a licensing and option agreement with Novartis for a drug candidate.